{"classes":[{"categories":[{"measurements":[{"comment":"Because there was no subject judged as \"PR\" or higher in this study.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"From initial response (PR or higher), DOR with relapse/recurrence or progression, and death, regardless of cause, as events, are to be summarized using the Kaplan-Meier estimator and the 50% point according to the Greenwood's formula and 95% confidence interval are to be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"OG000","title":"SyB L-0501"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to around 44 weeks","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Days"}